RGEN Valuation

Repligen Corp

Add to Watchlist

Advanced Chart

125.940

+3.64(2.976%)1D

Overview
Forecast
Valuation
Earnings

RGEN Relative Valuation

RGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGEN is overvalued; if below, it's undervalued.

Historical Valuation

Repligen Corp (RGEN) is now in the Fair zone, suggesting that its current forward PE ratio of 65.34 is considered Fairly compared with the five-year average of 85.87. The fair price of Repligen Corp (RGEN) is between 119.90 to 185.08 according to relative valuation methord.

Relative Value

Fair Zone

119.90-185.08

Current Price：125.94

Fair

65.34

Trailing

Forward

43.03

EV/EBITDA

Repligen Corp. (RGEN) has a current EV/EBITDA of 43.03. The 5-year average EV/EBITDA is 57.69. The thresholds are as follows: Strongly Undervalued below 27.82, Undervalued between 27.82 and 42.75, Fairly Valued between 72.63 and 42.75, Overvalued between 72.63 and 87.56, and Strongly Overvalued above 87.56. The current Forward EV/EBITDA of 43.03 falls within the Historic Trend Line -Fairly Valued range.

57.72

EV/EBIT

Repligen Corp. (RGEN) has a current EV/EBIT of 57.72. The 5-year average EV/EBIT is 72.11. The thresholds are as follows: Strongly Undervalued below 26.50, Undervalued between 26.50 and 49.30, Fairly Valued between 94.92 and 49.30, Overvalued between 94.92 and 117.72, and Strongly Overvalued above 117.72. The current Forward EV/EBIT of 57.72 falls within the Historic Trend Line -Fairly Valued range.

8.87

Repligen Corp. (RGEN) has a current PS of 8.87. The 5-year average PS is 14.50. The thresholds are as follows: Strongly Undervalued below 7.24, Undervalued between 7.24 and 10.87, Fairly Valued between 18.13 and 10.87, Overvalued between 18.13 and 21.76, and Strongly Overvalued above 21.76. The current Forward PS of 8.87 falls within the Undervalued range.

53.73

P/OCF

Repligen Corp. (RGEN) has a current P/OCF of 53.73. The 5-year average P/OCF is 62.81. The thresholds are as follows: Strongly Undervalued below 32.22, Undervalued between 32.22 and 47.51, Fairly Valued between 78.10 and 47.51, Overvalued between 78.10 and 93.40, and Strongly Overvalued above 93.40. The current Forward P/OCF of 53.73 falls within the Historic Trend Line -Fairly Valued range.

64.57

P/FCF

Repligen Corp. (RGEN) has a current P/FCF of 64.57. The 5-year average P/FCF is 105.26. The thresholds are as follows: Strongly Undervalued below 32.80, Undervalued between 32.80 and 69.03, Fairly Valued between 141.48 and 69.03, Overvalued between 141.48 and 177.71, and Strongly Overvalued above 177.71. The current Forward P/FCF of 64.57 falls within the Undervalued range.

Repligen Corp (RGEN) has a current Price-to-Book (P/B) ratio of 3.44. Compared to its 3-year average P/B ratio of 4.46 , the current P/B ratio is approximately -22.89% higher. Relative to its 5-year average P/B ratio of 5.58, the current P/B ratio is about -38.39% higher. Repligen Corp (RGEN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.20%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 0.87% , the current FCF yield is about -100.00% lower.

3.44

P/B

Median3y

4.46

Median5y

5.58

1.58

FCF Yield

Median3y

1.20

Median5y

0.87

Competitors Valuation Multiple

The average P/S ratio for RGEN's competitors is 0.47, providing a benchmark for relative valuation. Repligen Corp Corp (RGEN) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 14.81%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Rhythm Pharmaceuticals Inc

Regencell Bioscience Holdings Ltd

Loss

7.63B

JAZZ.O

Jazz Pharmaceuticals PLC

Loss

2.14%

7.90B

Performance Decomposition

Market capitalization of RGEN decreased by 17.82% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 3.60 to 8.15.

The secondary factor is the Revenue Growth, contributed 14.81%to the performance.

Overall, the performance of RGEN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

14.81%

158.84M → 182.37M

Revenue Growth

126.39%

3.60 → 8.15

Margin Expansion

-159.02%

863.88 → -509.86

P/E Change

-17.82%